Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: PEPCID COMPLETE

« Back to Dashboard
Pepcid Complete is a drug marketed by Mcneil Cons and is included in one NDA. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in PEPCID COMPLETE is calcium carbonate; famotidine; magnesium hydroxide. There are two hundred and thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the calcium carbonate; famotidine; magnesium hydroxide profile page.

Summary for Tradename: PEPCID COMPLETE

Suppliers: see list1

Clinical Trials for: PEPCID COMPLETE

Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)
Status: Completed Condition: Osteoarthritis; Rheumatoid Arthritis; Chronic Low Back Pain; Chronic Regional Pain Syndrome; Chronic Soft Tissue Pain

A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
Status: Completed Condition: Cancer

Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia
Status: Recruiting Condition: Aspirin; Dyspepsia

Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
Status: Recruiting Condition: Recurrent Breast Cancer; Metastatic Breast Cancer

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Status: Recruiting Condition: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mcneil Cons
calcium carbonate; famotidine; magnesium hydroxide
TABLET, CHEWABLE;ORAL020958Oct 16, 2000OTCYes5,989,588*PED<disabled>Y<disabled>
Mcneil Cons
calcium carbonate; famotidine; magnesium hydroxide
TABLET, CHEWABLE;ORAL020958Oct 16, 2000OTCYes6,814,978*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: PEPCID COMPLETE

Drugname Dosage Strength RLD Submissiondate
calcium carbonate/ famotadine/ magnesium hydroxideChewable Tablets800 mg/ 10 mg/ 165 mg (OTC)Pepcid Complete11/1/2004
« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn